Influenza Viruses and Vaccines: The Role of Vaccine Effectiveness Studies for Evaluation of the Benefits of Influenza Vaccines

Trombetta, Claudia Maria; Kistner, Otfried; Montomoli, Emanuele; Viviani, Simonetta; Marchi, Serena

doi:10.3390/vaccines10050714

Cited by 39 publications

(22 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The waning of VE may be an important measure while planning revaccinations in the future based on previous practices concerning other vaccine-preventable viral diseases (e.g., seasonal flu) [ 25 ]. The results of this study could be a reference for later data, as VE can be at its lowest value during an outbreak [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients: Lessons from the Delta Variant

Polivka,

Valyi-Nagy,

Szekanecz

et al. 2023

Vaccines

View full text Add to dashboard Cite

Although the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection against infection and severe disease can still be advantageous, especially for patients with COPD, who are more vulnerable to respiratory infections. The Hungarian COVID-19 registry was retrospectively investigated for risk of infection and hospitalization by time since the last vaccination, and vaccine effectiveness (VE) was calculated in adults with COPD diagnosis and an exact-matched control group during the Delta variant of concern (VOC) wave in Hungary (September–December 2021). For the matching, sex, age, major co-morbidities, vaccination status, and prior infection data were obtained on 23 August 2021. The study population included 373,962 cases divided into COPD patients (age: 66.67 ± 12.66) and a 1:1 matched group (age: 66.73 ± 12.67). In both groups, the female/male ratio was 52.2:47.7, respectively. Among the unvaccinated, there was no difference between groups in risk for infection or hospitalization. Regarding vaccinated cases, in the COPD group, a slightly faster decline in effectiveness was noted for hospitalization prevention, although in both groups, the vaccine lost its significant effect between 215 and 240 days after the last dose of vaccination. Based on a time-stratified multivariate Cox analysis of the vaccinated cases, the hazard was constantly higher in the COPD group, with an HR of 1.09 (95%: 1.05–1.14) for infection and 1.87 (95% CI: 1.59–2.19) for hospitalization. In our study, COPD patients displayed lower vaccine effectiveness against SARS-CoV-2 infection and hospitalization but a similar waning trajectory, as vaccines lost their preventive effect after 215 days. These data emphasize revaccination measures in the COPD patient population.

show abstract

Section: Discussionmentioning

confidence: 99%

Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients: Lessons from the Delta Variant

Polivka,

Valyi-Nagy,

Szekanecz

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Copy numbers were shown per 1 mL of the supernatant of the infected culture. 3) The copy number was below the limit of detection. This (98)…”

Section: Development Of In-vitro Potency Testing Methods For Cellbase...mentioning

confidence: 98%

“…The World Health Organization (WHO) estimates that annual influenza epidemics worldwide cause one billion cases of influenza, three to five million cases of severe illness, and approximately 290,000-650,000 respiratory deaths (1). Influenza vaccines are the most effective preventive measures against influenza infection and generally reduce the risk of influenza disease in the general population by 40-60% during influenza season, particularly when the circulating viral strains are antigenically well matched to the vaccine strains (2,3).…”

Section: Introductionmentioning

confidence: 99%

“…However, every year, the influenza virus evolves rapidly worldwide; therefore, propagation of the influenza virus in eggs is most likely a significant cause of an antigenic mismatch between the circulating influenza virus strains and the vaccine strains, reducing vaccine effectiveness (3). A sustainable and continuous cell-based influenza vaccine production system was developed in Japan to produce and supply vaccines that are effective and sufficient for pandemics and seasonal influenza preparedness.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Developments and current challenges in the process of cell culture-based seasonal influenza vaccine manufacture in Japan

Hamamoto

2024

GHM

View full text Add to dashboard Cite

Seasonal influenza is an acute respiratory infection primarily caused by influenza A and B viruses, which circulate annually and cause substantial morbidity and mortality worldwide. Annual influenza vaccination is currently the most effective measure for preventing influenza and greatly reduces the risk of disease severity and the incidence of complications and death. Annual seasonal influenza vaccines are traditionally produced in Japan and many other countries using viruses propagated in embryonated chicken eggs. However, at present, the effectiveness of the seasonal influenza vaccines has some significant limitations, partly because of egg-adaptive mutations in the antigenic sites of the influenza virus haemagglutinin, which are caused by the continued evolution of seasonal influenza viruses. To overcome the limitations of egg-based influenza vaccine production, a mammalian cell culture-based influenza vaccine production system has been developed in Japan in the past decade as an alternative to the current production method. In this review, I have summarised the progress in the development of cell-based seasonal influenza vaccines and discussed the technological challenges encountered in the development of influenza vaccines.

show abstract

“…The scientific publication Claudia Maria Trombetta et.al. [357] states, that children younger than 5 years old, and especially younger than 2 years old, have a higher risk of developing serious complications related to the flu. Children can also play a key role in the spread of influenza infection by shedding the virus in greater amounts and for longer than adults.…”

Section: дослідницькі центри компанії Rochementioning

confidence: 99%

Innovations in Modern Medicine and Biology

Vladlenov¹,

Chepurna²,

Korz³

et al. 2022

View full text Add to dashboard Cite

All rights reserved. Printed in the United States of America. No part of this publication may be reproduced, distributed, or transmitted, in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher. The content and reliability of the articles are the responsibility of the authors. When using and borrowing materials reference to the publication is required. Collection of scientific articles published is the scientific and practical publication, which contains scientific articles of students, graduate students, Candidates and Doctors of Sciences, research workers and practitioners from Europe and Ukraine. The articles contain the study, reflecting the processes and changes in the structure of modern science.

show abstract

Influenza Viruses and Vaccines: The Role of Vaccine Effectiveness Studies for Evaluation of the Benefits of Influenza Vaccines

Cited by 39 publications

References 99 publications

Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients: Lessons from the Delta Variant

Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients: Lessons from the Delta Variant

Developments and current challenges in the process of cell culture-based seasonal influenza vaccine manufacture in Japan

Innovations in Modern Medicine and Biology

Contact Info

Product

Resources

About